Chiesi Farmaceutici presents new TGF-β receptor type-1 inhibitors for IPF

Jan. 19, 2024

Chiesi Farmaceutici SpA has divulged TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).

BioWorld Science Respiratory Patents

Today's news in brief

BioWorld

BioWorld briefs for Aug. 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for August 14, 2025.

NME Digest: Q2 2025

BioWorld

A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...

Microscopic image of blood cells, chronic myeloid leukemia and thrombocytosis

Scemblix ticks Novartis earnings box; more ahead in CML

BioWorld

Novartis AG’s financial update included good news about Scemblix (asciminib), the first and only U.S. FDA-approved allosteric inhibitor for chronic myeloid...

Merck’s MK-2214 shows potential to slow Alzheimer’s pathology

BioWorld Science

Abnormal tau aggregation is a hallmark of Alzheimer’s disease (AD) and a major contributor to neurodegeneration, synaptic dysfunction, and progressive functional...